237 patents currently held
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Oct 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
58
Ending by 2030
Oct 2027
Next term end
135
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Mar 2029 · Low confidence
Also notable
Ends Jan 2038 · High confidence
Also notable
Ends Aug 2030 · High confidence
Also notable
Ends Feb 2032 · High confidence
Also notable
Ends Apr 2039 · High confidence
Also notable
Ends no later than Jun 2033 · Low confidence
Also notable
Ends Sep 2030 · High confidence
Also notable
Ends Feb 2037 · High confidence
Deuterium-Substituted Xanthine Derivatives and Methods of Use
US 8,987,442
Cited by 60 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Methods for Photodynamic Therapy
US 10,357,567
Cited by 41 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2038.
4-Hydroxybutyric Acid Analogs
US 8,461,197
Cited by 85 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
4-Hydroxybutyric Acid Analogs
US 8,759,394
The most cited patent in this portfolio, cited by 119 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2032.
Novel GLP-1 Analogues
US 11,447,535
Cited by 12 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Deuterated Derivatives of Ruxolitinib
US 9,249,149
Cited by 30 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Morphinan Compounds
US 8,710,072
Cited by 21 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Topical Cyclosporine-Containing Formulations and Uses Thereof
US 10,918,694
Cited by 6 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 21, 2026
- 1 fee due Dec 2, 2026The maintenance fee for Concentrated Aqueous Azalide Formulations (US 9,044,508) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
- 11 fees due Jan 2 to 23, 2027 · next Jan 2
- 4 fees due Feb 6 to 20, 2027 · next Feb 6
- 6 fees due Mar 10 to 29, 2027 · next Mar 10
- 4 fees due Apr 1 to 24, 2027 · next Apr 1
- 4 fees due May 3 to 21, 2027 · next May 3
- 2 fees due Jun 1 to 8, 2027 · next Jun 1
- 7 fees due Jul 7 to 26, 2027 · next Jul 7
- 7 fees due Aug 2 to 23, 2027 · next Aug 2
- 6 fees due Sep 1 to 30, 2027 · next Sep 1
- 2 fees due Oct 9 to 12, 2027 · next Oct 9
- 3 fees due Nov 3 to 17, 2027 · next Nov 3
Recent changes
- 5 of the patents on this record were granted since Aug 23, 2026
What they patent
The largest of its 135 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Substituted Xanthine Derivatives | 8 in force | to Feb 2030 |
| Adjustable Illuminator for Photodynamic Therapy and Diagnosis | 7 in force | to Feb 2038 |
| Morphinan Compounds | 7 in force | to Sep 2030 |
| Novel GLP-1 Analogues | 6 in force | to Jul 2039 |
| Methods for Photodynamic Therapy | 6 in force | to Jan 2038 |
| Duloxetine Sprinkles | 5 in force | to Sep 2038 |
| 4-Hydroxybutyric Acid Analogs | 5 in force | to Aug 2030 |
| Method of Injecting Octreotide Acetate into the Body | 4 in force | to Jan 2041 |
| Parenteral Unit Dosage Form of Dihydroergotamine | 4 in force | to Feb 2039 |
| Oral Liquid Compositions of Guanfacine | 4 in force | to Jul 2035 |
| Pharmaceutical Composition of Doxycycline | 4 in force | to Jul 2034 |
| Substituted ISOINDOLINE-1,3-Dione Derivatives | 4 in force | to Jun 2030 |
| Infusion Dosage Form of Norepinephrine | 3 in force | to Aug 2040 |
| Perfusion System | 3 in force | to May 2040 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,795,231 | Concentrated Aqueous Azalide Formulations In force · High confidence | In force | High confidence | |
| US 8,080,549 | Endothelin Receptor Antagonists In force · High confidence | In force | High confidence | |
| US 8,445,698 | A Process for the Preparation of an Intermediate of Tadalafil In force · High confidence | In force | High confidence | |
| US 8,664,265 | Stable Dosage Forms of Spiro and Dispiro 1,2,4-Trioxolane Antimalarials In force · Medium confidence | In force | Medium confidence | |
| US 8,318,754 | Novel Pyrimidinecarboxamide Derivatives In force · Low confidence | In force | Low confidence | |
| US 7,943,620 | Anti-Anginal Compounds In force · High confidence | In force | High confidence | |
| US 8,227,464 | Substituted Oxazolidinone Derivatives In force · High confidence | In force | High confidence | |
| US 7,985,750 | Substituted Oxazolidinone Derivatives In force · High confidence | In force | High confidence | |
| US 9,133,137 | Derivatives of Gefitinib In force · High confidence | In force | High confidence | |
| US 8,263,601 | Deuterium Substituted Xanthine Derivatives In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 237: 9 patents in force now held by others · 113 patents ended · 62 applications pending · 112 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.